Archives: Month: October 2025
-
October 20, 2025
Polygenic Risk Score May Help Personalize Risk Prediction for DCIS and LCIS
When someone is diagnosed with ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), one of the toughest questions is: What happens next? Not all in situ lesions progress to invasive cancer, yet many people feel pressure to treat aggressively for fear of missing something.
A new study from the American Association for Cancer Research suggests a promising—but still tentative—tool: a polygenic risk score (PRS), a number based on hundreds of inherited genetic variants. This approach may someday help personalize risk predictions for future breast events after an in situ diagnosis.
-
October 14, 2025
Are Death Rates from Breast Cancer After Initial DCIS Diagnosis Going Down? A New Study Raises Questions
When we talk about progress in breast cancer, we often point to the encouraging news that deaths from invasive breast cancer have steadily declined over recent decades—thanks to advances in detection, treatment and care.
But for DCIS, there is weak or even no evidence that our current treatments actually reduce the chance of dying from breast cancer. A new study published in Breast Cancer Research looked closely at this question, and the results raise important concerns.
-
October 2, 2025
Share Your Voice: New Clinical Trial Survey on Active Monitoring for DCIS
Here is an important opportunity to have your voice and preferences heard!
The COMET Study team has asked for DCIS Understood’s help with outreach about a new potential clinical trial utilizing active monitoring for low-risk DCIS. You can participate in this short survey even if your DCIS was high-grade. Your honest opinions are greatly appreciated!
